Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.8431

-0.0220

-2.54%

盘后0.8431

+0.00000.00%

18:48 EDT

High0.8600	Low0.8100	Vol45.59K
Open0.8600	D1 Closing0.8651	Amplitude5.78%
Mkt Cap75.63M	Tradable Cap34.19M	Total Shares89.70M
T/O38.02K	T/O Rate0.11%	Tradable Shares40.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":0.8431,"timestamp":1744920000000,"preClose":0.8651,"halted":0,"volume":45594,"hourTrading":{"tag":"盘后","latestPrice":0.8431,"preClose":0.8431,"latestTime":"18:48 EDT","volume":160,"amount":135.0896,"timestamp":1744930120667},"delay":0,"floatShares":40555355,"shares":89704194,"eps":-0.457495,"marketStatus":"Closed Good Friday","change":-0.022,"latestTime":"04-17 16:00:00 EDT","open":0.86,"high":0.86,"low":0.81,"amount":38017.280267999995,"amplitude":0.057797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.457495,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":0.8651,"preHourTrading":{"tag":"盘前","latestPrice":0.8668,"preClose":0.8651,"latestTime":"09:25 EDT","volume":3072,"amount":2487.3096192,"timestamp":1744896313262},"postHourTrading":{"tag":"盘后","latestPrice":0.8431,"preClose":0.8431,"latestTime":"18:48 EDT","volume":160,"amount":135.0896,"timestamp":1744930120667},"volumeRatio":0.5652938301551307},"requestUrl":"/m/hq/s/CNTX","defaultTab":"news","newsList":[{"id":"2526366996","title":"Context Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2526366996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526366996?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:39","pubTimestamp":1744202340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 09, 2025 08:39 ET (12:39 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CNTX"],"gpt_icon":0},{"id":"2526363159","title":"BRIEF-Context Therapeutics Doses First Patient In Phase 1 Clinical Trial Of Ct-95","url":"https://stock-news.laohu8.com/highlight/detail?id=2526363159","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526363159?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 20:10","pubTimestamp":1744200612,"startTime":"0","endTime":"0","summary":"BRIEF-Context Therapeutics Doses First Patient In Phase 1 Clinical Trial Of Ct-95April 9 (Reuters) - Context Therapeutics Inc CNTX.O:CONTEXT THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN18U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2526682123","title":"Context Therapeutics Begins Phase 1 Trial for CT-95","url":"https://stock-news.laohu8.com/highlight/detail?id=2526682123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526682123?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:57","pubTimestamp":1744199877,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) has issued an announcement. On April 9, 2025, Context Therapeutics announced the dosing of the first patient in it...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-begins-phase-1-trial-for-ct-95?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-begins-phase-1-trial-for-ct-95?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","CNTX"],"gpt_icon":0},{"id":"2526357038","title":"Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of Ct-95","url":"https://stock-news.laohu8.com/highlight/detail?id=2526357038","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526357038?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:30","pubTimestamp":1744198258,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN18U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2524378330","title":"Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos","url":"https://stock-news.laohu8.com/highlight/detail?id=2524378330","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524378330?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 20:51","pubTimestamp":1743771060,"startTime":"0","endTime":"0","summary":"Chicago, IL – April 4, 2025 – Stocks in this week’s article are Context Therapeutics Inc. CNTX, Blue Bird BLBD, Dycom Industries DY and Leidos LDOS.Bet on 4 Top-Ranked Stocks with Rising P/Es for Solid Gains. Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock's current market price does not adequately reflect its higher earnings, it suggests potential for growth.But there is more to this whole P/E story. Because not only low P/E, stocks with a rising P/E can also fetch strong returns. In this regard, investors can bet on the likes of Context Therapeutics Inc.,Blue Bird,Dycom Industries andLeidos.Blue Bird: The Zacks Rank #2 company is engaged in the designing, engineering, manufacturing and sale of school buses and related parts.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-context-125100297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BLBD","DY","BK4007","BK4129","CNTX","BK4123","LENZ","LU0006061336.USD","BK4149","BK4139","LDOS","BK4585"],"gpt_icon":0},{"id":"2524197931","title":"Context Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524197931","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524197931?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 19:30","pubTimestamp":1743507000,"startTime":"0","endTime":"0","summary":"PHILADELPHIA, April 01, 2025  -- Context Therapeutics Inc.  , a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences:. Stifel Virtual Targeted Oncology Forum, April 8-9, 2025Presentation: Tuesday, April 8 at 10:00 AM ET1x1 Meetings on April 8 – 9th. Jones Healthcare and Technology Innovation Conference in Las Vegas, April 8-9, 20251x1 Meetings on April 9th. 24th Annual Needham Virtual Healthcare Conference, April 7-10, 20251x1 Meetings on April 8th. Citizens Life Sciences Conference in New York City, May 7-8, 2025Presentation: Thursday, May 8 at 2:30 PM ET1x1 Meetings on May 8th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/context-therapeutics-participate-upcoming-investor-113000421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","CNTX"],"gpt_icon":0},{"id":"2521221279","title":"Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2521221279","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521221279?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 21:40","pubTimestamp":1742650840,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.Given this risk, we thought we'd take a look at whether Context Therapeutics  shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.Context Therapeutics has a market capitalisation of US$69m and burnt through US$29m last year, which is 42% of the company's market value. That's high expenditure relative to the value of the entire company, so if it does","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/companies-context-therapeutics-nasdaq-cntx-134040693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","USJW.SI","USAW.SI","BK4112","IE00B64PRP62.GBP","NQmain","LU2095319765.USD",".IXIC","TQQQ","IE00BKPKM429.USD","QLD","IE00B3QW5Z07.USD","LU2210149790.SGD","NVIW.SI","BK4585","IE00BGHQF748.EUR","SQQQ","LU2210150020.SGD","QID","MNQmain","BK4007","BK4588","NDAQ","PSQ","CNTX"],"gpt_icon":1},{"id":"2521400494","title":"Context Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400494","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400494?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 19:47","pubTimestamp":1742557620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 21, 2025 07:47 ET (11:47 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CNTX"],"gpt_icon":0},{"id":"2521494559","title":"BRIEF-Context Therapeutics Reports Full Year 2024 Operating And Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521494559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521494559?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 05:02","pubTimestamp":1742504538,"startTime":"0","endTime":"0","summary":"BRIEF-Context Therapeutics Reports Full Year 2024 Operating And Financial ResultsMarch 20 (Reuters) - Context Therapeutics Inc CNTX.O:CONTEXT THERAPEUTICS REPORTS FULL YEAR 2024 OPERATING AND FINANCIA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUAC72V2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX"],"gpt_icon":0},{"id":"2521979491","title":"Context Therapeutics FY 2024 GAAP EPS $(0.46) Beats $(0.58) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521979491","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521979491?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:48","pubTimestamp":1742503716,"startTime":"0","endTime":"0","summary":"Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.58) by 20.69 percent. This is a 69.33 percent increase over losses of $(1.50) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44426406/context-therapeutics-fy-2024-gaap-eps-0-46-beats-0-58-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","LENZ"],"gpt_icon":0},{"id":"2521995964","title":"Context Therapeutics Reports Full Year 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521995964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521995964?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:22","pubTimestamp":1742502157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUAC72V2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2521499662","title":"Context Therapeutics: Co Expects Its Cash and Cash Equivalents Will Continue to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499662?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:22","pubTimestamp":1742502157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUAC72V2J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2521504499","title":"Press Release: Context Therapeutics Reports Full Year 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2521504499","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521504499?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:22","pubTimestamp":1742502120,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents of $94.4 million as of December 31, 2024. Company expects its cash and cash equivalents will continue to fund operations into 2027. PHILADELPHIA, March 20, 2025  -- Context Therapeutics Inc.  , a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights.\"We ended the year with cash and cash equivalents of $94.4 million, providing the financial resources needed to further advance our clinical programs. Looking ahead, we anticipate dosing the first patient in our Phase 1 clinical trial of CT-95, targeting mesothelin-expressing cancers, in Q2 2025. Additionally, we expect to share initial clinical data from the CTIM-76 Phase 1 trial in the first half of 2026 and from the CT-95 Phase 1 trial in mid-2026. As we continue to progress, our focus remains on delivering innovative therapies th","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CNTX"],"gpt_icon":0},{"id":"2520889517","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520889517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520889517?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEVA","HYPR","OPTN","LPRO","CAL","FIVE","LQDA","ASO","LEN.B","BLTE","GLUE","LAR","SIG","DRI","KLC","OSS","CMC","MSIF","CELC","STTK","DERM","NOA","RWAY","SGMO","INO","ABSI","KOPN","LXEO","RANI","RBOT","SAIC","IMTX","NRXP","BCAB","AUTL","OABI","CBUS","DMAC","STNE","PL","SCPH","ANRO","CNTX","FLUX","PHUN","SPRY","BTM","LVTX"],"gpt_icon":1},{"id":"2519876572","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2519876572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519876572?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 18:00","pubTimestamp":1741946400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRSO","LE","LAR","RANI","ABSI","IDN","GOGO","AEVA","LXEO","GIS","LVTX","DTIL","HYPR","ERAS","AMPX","DTI","STNE","PL","HROW","CAL","HTHT","TME","OSS","FDX","GANX","INSE","ACN","FDS","JILL","LQDA","TYRA","DRI","MBRX","RLYB","SPRY","IFRX","MGNX","CNTX","LPRO","MRC","INKT","KOPN","AUTL","NRXP","CAPR","ANRO","NKTX"],"gpt_icon":1},{"id":"2514715701","title":"Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514715701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514715701?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 06:05","pubTimestamp":1740434756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nTUA5RK7G4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2503446416","title":"Sector Update: Health Care Stocks Rise Premarket Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2503446416","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503446416?lang=en_us&edition=full_marsco","pubTime":"2025-01-15 22:15","pubTimestamp":1736950552,"startTime":"0","endTime":"0","summary":"Health care stocks were rising premarket Wednesday, with The Health Care Select Sector SPDR Fund  up 0.8% and the iShares Biotechnology ETF  1.8% higher.Keros Therapeutics  shares were down 25% after the company said it has voluntarily halted all dosing in its phase 2 TROPOS trial for cibotercept in patients with pulmonary arterial hypertension due to \"new observations of pericardial effusion adverse events.\"NeoGenomics  stock was over 6% higher after the company said it expects 2025 total revenues in the range of $735 million to $745 million. Analysts surveyed by FactSet expect $727.8 million.Context Therapeutics  shares were more than 10% higher after the company said it has dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","XLV","BK4139","LU0012050646.USD","BK4121","IBB","NEO","KROS","BK4585","BK4581","LU0106261612.USD","CNTX","BK4588","BK4196"],"gpt_icon":0},{"id":"2503633959","title":"BRIEF-Context Therapeutics Says First Patient Dosed In The Phase 1 Clinical Trial Of CTIM-76","url":"https://stock-news.laohu8.com/highlight/detail?id=2503633959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503633959?lang=en_us&edition=full_marsco","pubTime":"2025-01-15 07:01","pubTimestamp":1736895681,"startTime":"0","endTime":"0","summary":"Jan 14  - Context Therapeutics   :   * CONTEXT THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE PHASE 1 CLINICAL TRIAL OF CTIM-76   * CONTEXT THERAPEUTICS INC - INITIAL DATA FOR CTIM-76 PHASE 1 TRIAL EXPECTED IN H1 2026Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","CNTX"],"gpt_icon":0},{"id":"2503638594","title":"Context Therapeutics Doses First Patient in Phase 1 Cancer Treatment Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2503638594","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503638594?lang=en_us&edition=full_marsco","pubTime":"2025-01-15 06:37","pubTimestamp":1736894241,"startTime":"0","endTime":"0","summary":"Context Therapeutics  said Tuesday it dosed the first patient in the phase 1 study of CTIM-76, its lead drug candidate targeting Claudin 6-positive gynecologic and testicular cancers.Initial data from the trial is expected to be released in H1 2026, the company said.The phase 1 trial seeks to evaluate the safety and efficacy of CTIM-76 in patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer.Up to 70 patients will be enrolled in the phase 1 trial to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity, including response rate, duration, and disease control, the company said.Shares of Context Therapeutics were up 1% in after-hours activity.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK4139","CNTX"],"gpt_icon":0},{"id":"2503638394","title":"Context Therapeutics Advances CTIM-76 in Clinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2503638394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503638394?lang=en_us&edition=full_marsco","pubTime":"2025-01-15 06:28","pubTimestamp":1736893727,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Context Therapeutics ( ($CNTX) ). On January 14, 2025, Context Therapeutics announced that the first patient ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-advances-ctim-76-in-clinical-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-advances-ctim-76-in-clinical-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CNTX","LENZ","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.2411},{"period":"1month","weight":0.0605},{"period":"3month","weight":-0.1652},{"period":"6month","weight":-0.5867},{"period":"1year","weight":-0.3935},{"period":"ytd","weight":-0.197}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.041474},{"month":2,"riseRate":0.25,"avgChangeRate":-0.065627},{"month":3,"riseRate":0.5,"avgChangeRate":-0.053897},{"month":4,"riseRate":0.5,"avgChangeRate":0.013409},{"month":5,"riseRate":1,"avgChangeRate":0.504922},{"month":6,"riseRate":0.666667,"avgChangeRate":0.266045},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.114577},{"month":8,"riseRate":0.666667,"avgChangeRate":0.026866},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.051007},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.016878},{"month":11,"riseRate":0.5,"avgChangeRate":-0.052796},{"month":12,"riseRate":0.25,"avgChangeRate":-0.280231}],"exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}